Unión Europea - español - EMA (European Medicines Agency)

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

distribuidora drogueria sagitario s.r.l. - droguerÍa - capsula - por capsula - - sangre y Órganos formadores de sangre

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

seven pharma s.a.c. - droguerÍa - capsula - por capsula - - sangre y Órganos formadores de sangre

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

elea peru s.a.c. - droguerÍa - capsula dura - por capsula - - agentes antineoplÁsicos e inmunomoduladores